Ljupco/iStock via Getty Images
- Zealand Pharma (ZLDPF) has signed a licensing and collaboration agreement with Shanghai-based OTR Therapeutics to develop new therapies for metabolic diseases.
- Terms call for OTR to receive an upfront payment $20M (could rise to $30M under certain conditions) and potential milestone payments of ~$2.5B, plus tiered